<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="letter">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">BW8jGdS5dJg3kRXbCDSQR7Q</article-id>
      <article-id pub-id-type="other">00009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000500009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600509</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000031</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Associa&#231;&#227;o do &#237;ndice tornozelo-bra&#231;o com inflama&#231;&#227;o e altera&#231;&#245;es minerais &#243;sseas em pacientes em hemodi&#225;lise</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Miguel</surname>
            <given-names>Jair B.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matos</surname>
            <given-names>Jorge P. Strogoff de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ruzany</surname>
            <given-names>Frederico</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miguel</surname>
            <given-names>Claudia S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miguel</surname>
            <given-names>Sebasti&#227;o J. S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Naveiro</surname>
            <given-names>Luiz T.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lugon</surname>
            <given-names>Jocemir R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Niteroi</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal Fluminense</institution>
        <institution content-type="orgdiv1">Departmento de Medicina </institution>
        <institution content-type="orgdiv2">Divis&#227;o de Nefrologia</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Santo Ant&#244;nio de P&#225;dua</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Cl&#237;nica de Doen&#231;as Renais</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Cl&#237;nica de Doen&#231;as Renais</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>05</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>5</issue>
      <fpage>405</fpage>
      <lpage>410</lpage>
      <history>
        <date date-type="rev-recd">
          <day>20</day>
          <month>10</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>16</day>
          <month>08</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>10</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: O &#237;ndice tornozelo-bra&#231;o (ITB) reduzido, inflama&#231;&#227;o e dist&#250;rbio mineral &#243;sseo (DMO) est&#227;o associados com aumento no risco de morte e complica&#231;&#245;es cardiovasculares em pacientes em hemodi&#225;lise (HD), mas a rela&#231;&#227;o entre esses fatores necessita ser elucidada. OBJETIVO: Avaliar a associa&#231;&#227;o entre ITB anormal e DMO com inflama&#231;&#227;o em pacientes em HD. M&#201;TODOS: Esta an&#225;lise transversal avaliou 478 pacientes em HD por pelo menos 1 ano. O ITB foi avaliado atrav&#233;s de um Doppler port&#225;til e man&#244;metro de coluna de merc&#250;rio. Os pacientes foram divididos em tr&#234;s grupos, de acordo com o ITB (baixo: &lt;0,9, normal: 0,9 a 1,3, e alto: &gt;1,3). As medidas de prote&#237;na C-reativa foram utilizadas como marcador inflamat&#243;rio, enquanto a DMO foi avaliada atrav&#233;s dos n&#237;veis de c&#225;lcio, f&#243;sforo e horm&#244;nio paratireoidiano intacto (iPTH). RESULTADOS: Os participantes tinham 54 (18 a 75) anos, 56% eram do sexo masculino, 17% eram diab&#233;ticos e estavam em HM por 5 (1 a 35) anos. A preval&#234;ncia de ITB baixo, normal e alto AAI foi 26,8%, 64,6% e 8,6%, respectivamente. Usando um modelo de regress&#227;o log&#237;stica condicional com procedimento backward, idade (p&lt;0,001), diabetes (p= 0,001), e n&#237;veis de prote&#237;na C-reativa &gt;6 mg/L (p= 0,006) estavam associados com a presen&#231;a de ITB baixo, enquanto o sexo masculino (p&lt;0,001), diabetes (p= 0,001) e produto c&#225;lcio x f&#243;sforo elevado (p= 0,026) estavam associados com ITB alto. CONCLUS&#195;O: Em pacientes em HD, a presen&#231;a de diabetes estava associada com ITB alto e baixo. O risco de ter ITB baixo parece aumentar com a idade e inflama&#231;&#227;o, enquanto a DMO estava associada com ITB alto.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>&#205;ndice tornozelo-bra&#231;o</kwd>
        <kwd>inflama&#231;&#227;o</kwd>
        <kwd>calcinose</kwd>
        <kwd>di&#225;lise renal</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>18</day>
        <month>03</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO ORIGINAL</bold>
    </p>
    <p>Associa&#231;&#227;o do &#237;ndice tornozelo-bra&#231;o com inflama&#231;&#227;o e altera&#231;&#245;es minerais &#243;sseas em pacientes em hemodi&#225;lise</p>
    <p>
      <bold>Jair B. Miguel<sup>I,II</sup>; Jorge P. Strogoff de Matos<sup>I</sup>; Frederico Ruzany<sup>III</sup>; Claudia S. Miguel<sup>II</sup>; Sebasti&#227;o J. S. Miguel<sup>II</sup>; Luiz T. Naveiro<sup>I</sup>; Jocemir R. Lugon<sup>I</sup></bold>
    </p>
    <p><sup>I</sup>Divis&#227;o de Nefrologia, Departmento de Medicina, Universidade Federal Fluminense, Niteroi, RJ - Brasil </p>
    <p><sup>II</sup>Clinefron, Cl&#237;nica de Doen&#231;as Renais, Santo Ant&#244;nio de P&#225;dua, RJ - Brasil </p>
    <p><sup>III</sup>CDR, Cl&#237;nica de Doen&#231;as Renais, Rio de Janeiro, RJ - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> O &#237;ndice tornozelo-bra&#231;o (ITB) reduzido, inflama&#231;&#227;o e dist&#250;rbio mineral &#243;sseo (DMO) est&#227;o associados com aumento no risco de morte e complica&#231;&#245;es cardiovasculares em pacientes em hemodi&#225;lise (HD), mas a rela&#231;&#227;o entre esses fatores necessita ser elucidada. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a associa&#231;&#227;o entre ITB anormal e DMO com inflama&#231;&#227;o em pacientes em HD. </p>
    <p><bold>M&#201;TODOS:</bold> Esta an&#225;lise transversal avaliou 478 pacientes em HD por pelo menos 1 ano. O ITB foi avaliado atrav&#233;s de um Doppler port&#225;til e man&#244;metro de coluna de merc&#250;rio. Os pacientes foram divididos em tr&#234;s grupos, de acordo com o ITB (baixo: &lt;0,9, normal: 0,9 a 1,3, e alto: &gt;1,3). As medidas de prote&#237;na C-reativa foram utilizadas como marcador inflamat&#243;rio, enquanto a DMO foi avaliada atrav&#233;s dos n&#237;veis de c&#225;lcio, f&#243;sforo e horm&#244;nio paratireoidiano intacto (iPTH). </p>
    <p><bold>RESULTADOS:</bold> Os participantes tinham 54 (18 a 75) anos, 56% eram do sexo masculino, 17% eram diab&#233;ticos e estavam em HM por 5 (1 a 35) anos. A preval&#234;ncia de ITB baixo, normal e alto AAI foi 26,8%, 64,6% e 8,6%, respectivamente. Usando um modelo de regress&#227;o log&#237;stica condicional com procedimento <italic>backward</italic>, idade (p&lt;0,001), diabetes (p= 0,001), e n&#237;veis de prote&#237;na C-reativa <underline>&gt;</underline>6 mg/L (p= 0,006) estavam associados com a presen&#231;a de ITB baixo, enquanto o sexo masculino (p&lt;0,001), diabetes (p= 0,001) e produto c&#225;lcio x f&#243;sforo elevado (p= 0,026) estavam associados com ITB alto. </p>
    <p><bold>CONCLUS&#195;O:</bold> Em pacientes em HD, a presen&#231;a de diabetes estava associada com ITB alto e baixo. O risco de ter ITB baixo parece aumentar com a idade e inflama&#231;&#227;o, enquanto a DMO estava associada com ITB alto.</p>
    <p><bold>Palavras-chave: </bold> &#205;ndice tornozelo-bra&#231;o, inflama&#231;&#227;o, calcinose, di&#225;lise renal.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A taxa de mortalidade em pacientes com Doen&#231;a Renal Cr&#244;nica (DRC) terminal &#233; muito alta e a maior causa de morte &#233; doen&#231;a cardiovascular (DCV)<sup>1</sup>. Esse impacto da DCV tem sido atribu&#237;do &#224; fatores de risco tradicionais e n&#227;o-tradicionais, que est&#227;o relacionados &#224; doen&#231;a renal cr&#244;nica e/ou procedimento de di&#225;lise. Idade, diabetes mellitus e tabagismo s&#227;o fatores tradicionais tamb&#233;m aplic&#225;veis &#224; pacientes em di&#225;lise<sup>2</sup>. Entre os fatores de risco n&#227;o-tradicionais, dist&#250;rbio mineral &#243;sseo (DMO), incluindo altos n&#237;veis de f&#243;sforo, produto c&#225;lcio x f&#243;sforo alto e n&#237;veis s&#233;ricos extremos de horm&#244;nio paratireoidiano intacto (iPTH) tem sido associados com aumento do risco de mortalidade cardiovascular<sup>3-5</sup>. Outro fator de risco n&#227;o-tradicional para morte cardiovascular &#233; a microinflama&#231;&#227;o, geralmente avaliada atrav&#233;s dos n&#237;veis s&#233;ricos de prote&#237;na C-reativa (PCR)<sup>6</sup>. </p>
    <p>Al&#233;m de doen&#231;a arterial coronariana e doen&#231;a vascular cerebral, doen&#231;a arterial perif&#233;rica (DAP) tamb&#233;m &#233; altamente prevalente em pacientes em di&#225;lise e sua presen&#231;a tem sido associada com alta mortalidade<sup>7-10</sup>. O &#237;ndice tornozelo-bra&#231;o (ITB) tem sido utilizado como uma ferramenta diagn&#243;stica para DAP<sup>11</sup>. O &#237;ndice &#233; baseado no fato de que a press&#227;o arterial sist&#243;lica nas pernas &#233; geralmente igual ou levemente mais alta do que nos membros superiores de indiv&#237;duos saud&#225;veis. Na presen&#231;a de uma estenose arterial, uma redu&#231;&#227;o na press&#227;o ocorre em posi&#231;&#227;o distal &#224; les&#227;o<sup>12</sup>. Quando a angiografia era utilizada como o padr&#227;o-ouro, uma raz&#227;o ITB &lt; 0.9 era considerada de alta sensibilidade e especificidade no diagn&#243;stico de DAP<sup>11</sup>. Al&#233;m disso, um ITB baixo apresenta uma forte correla&#231;&#227;o com doen&#231;a arterial em outros s&#237;tios e tem se mostrado um bom preditor de mortalidade na popula&#231;&#227;o em geral<sup>7-10,13,14</sup>.</p>
    <p>Tanto o ITB baixo quanto o alto tem se mostrado fortes preditores de morte em pacientes em hemodi&#225;lise (HD)<sup>7-10,13,14</sup>. &#201; presum&#237;vel considerar que um ITB alto em pacientes com DRC terminal pode ser devido &#224; calcifica&#231;&#227;o vascular e rigidez da parede arterial associada com DMO.</p>
    <p>O objetivo desse estudo foi avaliar a associa&#231;&#227;o entre valores de ITB altos e baixos em pacientes em HD, com v&#225;rios fatores de risco cardiovasculares n&#227;o-tradicionais, a saber, inflama&#231;&#227;o e DMO. </p>
    <p>
      <bold>Materiais e m&#233;todos</bold>
    </p>
    <p>Esse &#233; um estudo transversal e multic&#234;ntrico, realizado em seis cl&#237;nicas de di&#225;lise no estado do Rio de Janeiro, Brasil. O estudo foi aprovado pelo Comit&#234; de &#201;tica local e todos os pacientes assinaram o termo de consentimento informado. Os estudos de imagens e medidas do ITB foram realizados entre mar&#231;o de 2006 e setembro de 2007. Todos os pacientes com idade de 18 a 75 anos, que estavam em HD por pelo menos 12 meses foram convidados a participar do estudo. Os crit&#233;rios de exclus&#227;o foram: diagn&#243;stico de neoplasia, presen&#231;a de teste anti-HIV positivo, fibrila&#231;&#227;o atrial, amputa&#231;&#227;o bilateral de membros inferiores e dem&#234;ncia. </p>
    <p>
      <bold>O &#237;ndice tornozelo-bra&#231;o </bold>
    </p>
    <p>Os pacientes foram avaliados uma vez para obten&#231;&#227;o do &#237;ndice tornozelo-bra&#231;o (ITB). As medidas foram realizadas antes da sess&#227;o de HD, ap&#243;s 5 minutos na posi&#231;&#227;o supina. O ITB, definido como a raz&#227;o entre a press&#227;o arterial sist&#243;lica do tornozelo e a do bra&#231;o, foi medido por tr&#234;s observadores treinados (um m&#233;dico e dois estudantes de Medicina), com base na informa&#231;&#227;o de que a variabilidade inter-observador e intra-observador para medida de press&#227;o arterial por Doppler &#233; insignificante<sup>7,15</sup>. Nos membros inferiores, as art&#233;rias posteriores tibiais foram utilizadas, considerando que a art&#233;ria <italic>dorsalis pedis</italic> est&#225; congenitamente ausente em 4 a 12% da popula&#231;&#227;o<sup>11</sup>. A press&#227;o arterial sist&#243;lica (PAS) foi medida duas vezes em cada s&#237;tio, em uma sucess&#227;o alternada e r&#225;pida, a fim de obter-se um valor m&#233;dio. Manguitos padr&#227;o para medir a PA foram aplicados ao bra&#231;o e &#224; cada tornozelo (com a extremidade inferior da p&#234;ra posicionada exatamente acima dos mal&#233;olos). Ap&#243;s a palpa&#231;&#227;o das art&#233;rias, gel para ultrassom foi aplicado e um estetosc&#243;pio Doppler (10 MHz, Super Dupplex, Huntleigh Technology Inc., Manalapan NJ, EUA) foi utilizado para avaliar a PAS. A PAS no membro superior foi medida na arterial braquial do bra&#231;o contralateral ao acesso vascular. Para calcular o ITB, a menor m&#233;dia dos tornozelos foi dividida pela m&#233;dia do bra&#231;o<sup>16</sup>. </p>
    <p>Para avaliar a rela&#231;&#227;o entre o ITB e os dados demogr&#225;ficos, cl&#237;nicos e laboratoriais, a popula&#231;&#227;o foi dividida em tr&#234;s grupos, de acordo com os valores do ITB: grupo com ITB baixo (&lt;0,9), grupo com ITB normal (0,9 a 1,3) e grupo com ITB alto (&gt;1,3).</p>
    <p>
      <bold>Dados demogr&#225;ficos, cl&#237;nicos e laboratoriais</bold>
    </p>
    <p>Dados cl&#237;nicos e demogr&#225;ficos foram obtidos atrav&#233;s de uma entrevista cl&#237;nica estruturada e o banco de dados utilizado em todas as seis cl&#237;nicas de di&#225;lise. Esses dados incluem sexo, idade, etnia, tempo de di&#225;lise, doen&#231;a renal prim&#225;ria, acesso vascular, tabagismo atual (sim/n&#227;o) e uso de medicamentos (acetato de c&#225;lcio, carbonato de c&#225;lcio, calcitriol, sevelamer e eritropoetina). Comorbidades foram definidas como: hipertens&#227;o (PAS pr&#233;-di&#225;lise <underline>&gt;</underline>140 mmHg e/ou press&#227;o arterial diast&#243;lica (PAD) <underline>&gt;</underline>90 mmHg e/ou uso de medica&#231;&#245;es anti-hipertensivas); doen&#231;a arterial coronariana (angina de esfor&#231;o, uso atual de vasodilatador coron&#225;rio, infarto do mioc&#225;rdio pr&#233;vio e cirurgia de revasculariza&#231;&#227;o ou angioplastia pr&#233;vias); sequelas de derrame; DAP (uso atual de vasodilatador perif&#233;rico, cirurgia de revasculariza&#231;&#227;o de membro inferior ou angioplastia ou amputa&#231;&#227;o n&#227;o-traum&#225;tica de membro inferior); diabetes mellitus (nefropatia diab&#233;tica como doen&#231;a renal prim&#225;ria ou diagn&#243;stico cl&#237;nico ap&#243;s in&#237;cio da terapia de substitui&#231;&#227;o renal) paratireoidectomia; e soropositividade para hepatite C.</p>
    <p>Valores de hemoglobina, creatinina e Kt/V equilibrado (eKt/V) foram definidos atrav&#233;s da m&#233;dia das tr&#234;s ultimas medidas mais pr&#243;ximas &#224; medida do ITB. A fim de melhor analisar o impacto da DMO nos achados, exposi&#231;&#227;o cumulativa foi avaliada atrav&#233;s do c&#225;lculo da m&#233;dia de todas as medidas dos valores s&#233;ricos para c&#225;lcio, f&#243;sforo e horm&#244;nio paratireoidiano intacto (iPTH) durante um per&#237;odo de 36 meses exatamente anterior &#224; avalia&#231;&#227;o do ITB ou desde o in&#237;cio da HD em pacientes submetidos a terapia de substitui&#231;&#227;o renal por menos de 3 anos. Os n&#237;veis s&#233;ricos de c&#225;lcio e f&#243;sforo foram medidos mensalmente, os n&#237;veis de iPTH, a cada seis meses. As an&#225;lises de sangue de rotina foram realizadas no mesmo laborat&#243;rio. Um ensaio imunoturbidim&#233;trico de alta sensibilidade para prote&#237;na C-reativa (PCR) foi especificamente utilizado para o estudo e os valores mostrados foram determinados na mesma &#233;poca que o ITB foi medido. </p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>As vari&#225;veis cont&#237;nuas foram apresentadas como m&#233;dia &#177; DP, se os dados seguissem uma distribui&#231;&#227;o normal e como mediana e varia&#231;&#227;o se a distribui&#231;&#227;o dos dados fosse n&#227;o-Gaussiana. As vari&#225;veis categ&#243;ricas foram mostradas como freq&#252;&#234;ncias. As diferen&#231;as entre os grupos ITB foram avaliadas atrav&#233;s do teste ANOVA one-way, complementado pelo teste de Bonferroni ou Kruskal-Wallis ANOVA complementado pelo teste de Dunn, quando apropriado. A an&#225;lise das freq&#252;&#234;ncias foi realizada atrav&#233;s do teste exato de Fisher. A associa&#231;&#227;o entre as vari&#225;veis e o risco de apresentar ITB baixo foi estudada atrav&#233;s de regress&#227;o log&#237;stica condicional com t&#233;cnica <italic>backward</italic>. Idade, sexo, diabetes, tabagismo, tempo de di&#225;lise, albumina s&#233;rica, PCR, c&#225;lcio, f&#243;sforo, produto c&#225;lcio x f&#243;sforo e iPTH foram inclu&#237;dos na fase inicial. A mesma an&#225;lise foi realizada para avaliar as vari&#225;veis associadas com o risco de apresentar ITB alto. Um valor de P&lt;0,05 foi considerado significante. O software SPSS, vers&#227;o 17.0 foi utilizada na an&#225;lise estat&#237;stica. </p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>De um total de 1.170 pacientes com DRC terminal em HD de manuten&#231;&#227;o nas seis cl&#237;nicas, 478 pacientes foram inclu&#237;dos no estudo. As caracter&#237;sticas gerais dos pacientes s&#227;o mostradas na <xref ref-type="table" rid="tab01">Tabela 1</xref>. A mediana da idade era 53,6 (18 a 75) anos; 56% dos pacientes eram do sexo masculino, 16,9% eram diab&#233;ticos e 50,6% tinham hipertens&#227;o como doen&#231;a renal prim&#225;ria. A mediana do tempo de di&#225;lise era de 59 (12 a 427) meses, com 27% dos pacientes em di&#225;lise por menos de 3 anos. Os valores dos par&#226;metros laboratoriais selecionados foram: eKt/V 1,51&#177;0,40; hemoglobina 11,4&#177;1,6 g/dl; albumina s&#233;rica 3,8&#177;0,3 g/dl; PCR 4,7 (0,1 - 150) mg/l; &#237;on c&#225;lcio 4,6&#177;0,3 mg/dl; f&#243;sforo 5,4&#177;1,2 mg/dL; e i-PTH 370 (10 a 2.500) pg/ml.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt01.jpg"/></table-wrap>
    <p>As preval&#234;ncias de ITB baixo, normal e alto foram 26,8%, 64,6% e 8,6%, respectivamente. A <xref ref-type="table" rid="tab02">Tabela 2</xref> mostra as caracter&#237;sticas de cada grupo ITB.</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt02.jpg"/></table-wrap>
    <p>Pacientes no grupo ITB baixo eram significantemente mais velhos do que aqueles nos grupos ITB normal e ITB alto. O sexo masculino prevaleceu no grupo com ITB alto, quando comparado aos grupos ITB normal e baixo. As preval&#234;ncias de diabetes, DAP e amputa&#231;&#227;o n&#227;o-traum&#225;tica foram significantemente mais baixas no grupo ITB normal do que no grupo ITB baixo e ITB alto. Doen&#231;a arterial coronariana (DAC) e sequela de derrame foram mais frequentes no grupo com ITB baixo do que no grupo com ITB normal. Nenhuma diferen&#231;a foi observada em rela&#231;&#227;o &#224;s medidas de press&#227;o arterial ou press&#227;o de pulso entre os grupos de ITB (dados n&#227;o mostrados). </p>
    <p>Os achados laboratoriais por grupo de ITB s&#227;o mostrados na <xref ref-type="table" rid="tab03">Tabela 3</xref>. O grupo com ITB baixo mostrava n&#237;veis mais altos de PCR e mais baixos de albumina s&#233;rica do que o grupo com ITB normal. Os n&#237;veis de creatinina s&#233;rica eram mais baixos no grupo com ITB baixo, quando comparado aos grupos com ITB normal e alto. O grupo com ITB alto apresentava aumento nos n&#237;veis de f&#243;sforo s&#233;rico e produto c&#225;lcio x f&#243;sforo, quando comparado aos grupos com ITB normal e alto. O grupo com ITB alto apresentava aumento dos n&#237;veis de iPTH, quando comparado ao grupo com baixo ITB. </p>
    <table-wrap id="tab03">
      <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt03.jpg"/></table-wrap>
    <p>Na an&#225;lise de regress&#227;o, apenas idade, diabetes e n&#237;veis elevados de PCR estavam significantemente associados com o risco de apresentar ITB baixo (<xref ref-type="table" rid="tab04">Tabela 4</xref>), enquanto as vari&#225;veis associadas com o risco de apresentar ITB baixo eram sexo masculino, diabetes e produto c&#225;lcio x f&#243;sforo elevado (<xref ref-type="table" rid="tab05">Tabela 5</xref>).</p>
    <table-wrap id="tab04">
      <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt04.jpg"/></table-wrap>
    <table-wrap id="tab05">
      <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt05.jpg"/></table-wrap>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>No presente estudo, a alta preval&#234;ncia de ITB anormal, na maioria ITB baixo, foi observada em pacientes em HD de manuten&#231;&#227;o. </p>
    <p>A mensura&#231;&#227;o do ITB &#233; um teste f&#225;cil, confi&#225;vel e n&#227;o-invasivo, o qual &#233; um marcador de doen&#231;a vascular ateroscler&#243;tica, bem como um preditor de mortalidade na popula&#231;&#227;o em geral e em pacientes em HD<sup>9,10,13,14</sup>.</p>
    <p>As doen&#231;as cardiovasculares tem sido apontadas como a principal causa de morte em pacientes em di&#225;lise<sup>1</sup>. Ambos os fatores de risco tradicionais e n&#227;o-tradicionais relacionados &#224; doen&#231;a renal cr&#244;nica e/ou procedimento de di&#225;lise est&#227;o envolvidos nesse processo. Entre os fatores de risco de DCV n&#227;o-tradicionais, a DMO, inflama&#231;&#227;o e tempo de di&#225;lise tem sido amplamente explorados<sup>3-6</sup>. Entretanto, uma liga&#231;&#227;o entre ITB anormal e tais fatores de risco n&#227;o-tradicionais est&#225; faltando. </p>
    <p>Enfatizando o papel do ITB como marcador substituto de aterosclerose generalizada, observamos que o grupo com ITB baixo apresentava uma preval&#234;ncia mais alta de DCV. </p>
    <p>Como esperado, observou-se que diabetes estava associada com aumento no risco de baixo ITB. No presente estudo, a diabetes tamb&#233;m estava associada com aumento no risco de ITB alto. Isso pode ser atribu&#237;do &#224; maior preval&#234;ncia de calcifica&#231;&#227;o vascular em tais pacientes, o que promove rigidez arterial e press&#227;o arterial mais elevada nos membros inferiores<sup>10</sup>. A predomin&#226;ncia de pacientes mais velhos no grupo com ITB baixo em nosso estudo est&#225; de acordo com estudos anteriores que avaliaram popula&#231;&#245;es em geral e aquelas em HD<sup>9,10,13,14</sup>. Observamos que o risco de apresentar ITB baixo quase dobra para cada d&#233;cada adicional. Esse achado refor&#231;a idade como um fator de risco tradicional para DAP em pacientes em HD. </p>
    <p>Os pacientes com ITB baixo apresentaram n&#237;veis de PCR mais altos e n&#237;veis s&#233;ricos mais baixos de albumina e creatinina. Esses achados n&#227;o s&#227;o inesperados, considerando que a associa&#231;&#227;o de desnutri&#231;&#227;o e inflama&#231;&#227;o com doen&#231;a ateroscler&#243;tica e DAP, em popula&#231;&#245;es em geral e em HD, &#233; bem conhecida<sup>17-19</sup>. Na an&#225;lise de regress&#227;o, o n&#237;vel da PCR <underline>&gt;</underline>6 mg/l foi a &#250;nica vari&#225;vel laboratorial associada com o risco de apresentar ITB baixo. Pacientes em HD geralmente apresentam n&#237;veis de PCR muito mais altos do que aqueles vistos na popula&#231;&#227;o em geral. Assim, n&#237;veis de PCR <underline>&gt;</underline> 6 mg/dl foi uma defini&#231;&#227;o pr&#233;-especificada de anormalidade adotada pelas cl&#237;nicas de di&#225;lise participantes do estudo. </p>
    <p>O n&#237;vel de fosfato s&#233;rico foi mais alto em pacientes com ITB alto, provavelmente refletindo seu papel na calcifica&#231;&#227;o vascular, j&#225; que art&#233;rias calcificadas s&#227;o mais r&#237;gidas e apresentam press&#227;o arterial mais elevada<sup>10</sup>. Nenhuma diferen&#231;a foi observada nos n&#237;veis s&#233;ricos de c&#225;lcio de acordo com a classifica&#231;&#227;o do ITB. Na an&#225;lise de regress&#227;o, a &#250;nica vari&#225;vel laboratorial associada com o risco de apresentar ITB alto foi o produto c&#225;lcio x f&#243;sforo. Nenhum marcador de DMO foi associado com o risco de ter ITB baixo. Deve ser enfatizado que, no presente estudo, utilizamos as m&#233;dias das medidas de c&#225;lcio, fosfato e iPTH realizadas ao longo de um per&#237;odo de 36 meses anterior &#224; avalia&#231;&#227;o do ITB ou desde o in&#237;cio da terapia de substitui&#231;&#227;o renal para aqueles indiv&#237;duos em HD h&#225; menos de 3 anos. Defici&#234;ncia de vitamina D tem sido reconhecida como um fator de risco n&#227;o-tradicional para aterosclerose e desfechos cardiovasculares adversos<sup>20</sup>. A defici&#234;ncia de 25-hidroxivitamina D e sua forma ativa 1,25-dihidroxivitamina D &#233; altamente prevalente em pacientes em HD<sup>21,22</sup>. Acreditamos que algumas anormalidades vasculares observadas em nosso estudo poderiam ser pelo menos parcialmente atribu&#237;das &#224; defici&#234;ncia de vitamina D. Como n&#227;o foi poss&#237;vel medir os n&#237;veis s&#233;ricos de vitamina D, essa quest&#227;o n&#227;o foi analisada em nosso estudo. </p>
    <p>Nenhuma associa&#231;&#227;o foi detectada entre o tempo de di&#225;lise e o risco de apresentar ITB alto ou baixo. Por conseguinte, a DAP n&#227;o parece ser uma complica&#231;&#227;o da insufici&#234;ncia renal e/ou terapia de apoio, mas uma consequ&#234;ncia de outras condi&#231;&#245;es, principalmente envelhecimento e diabetes. Achado similar foi demonstrado por Cheung e cols.<sup>10</sup>, mas n&#227;o por Rajagopalan e cols.<sup>8</sup>, que observaram uma correla&#231;&#227;o positiva entre tempo de di&#225;lise e DAP. </p>
    <p>Em nossa an&#225;lise, a hipertens&#227;o n&#227;o estava associada com ITB alto ou baixo, uma observa&#231;&#227;o tamb&#233;m relatada por Cheung e cols.<sup>2 </sup>e Jaar e cols.<sup>23</sup>. A hipertens&#227;o est&#225; amplamente presente em pacientes em HD, com uma preval&#234;ncia que pode chegar a 80% em algumas popula&#231;&#245;es, tornando a identifica&#231;&#227;o de seu efeito sobre um subgrupo espec&#237;fico dif&#237;cil de demonstrar<sup>24</sup>. </p>
    <p>Deve ser enfatizado que Rajagopalan e cols.<sup>8</sup> observaram uma associa&#231;&#227;o positiva entre hipertens&#227;o e DAP, demonstrando que os dados, em rela&#231;&#227;o a essa quest&#227;o, n&#227;o s&#227;o consensuais. </p>
    <p>Surpreendentemente, n&#227;o observamos uma associa&#231;&#227;o entre tabagismo e risco de ITB anormal. Talvez a baixa preval&#234;ncia de tabagismo em nossa popula&#231;&#227;o possa ter abrandado esse efeito. A rela&#231;&#227;o entre tabagismo e DAP em pacientes em HD foi demonstrada por Cheung e cols.<sup>2</sup> e Rajagopalan e cols.<sup>8</sup>, mas n&#227;o por Ono e cols.<sup>10</sup>.</p>
    <p>Observamos uma predomin&#226;ncia de indiv&#237;duos do sexo masculino entre os pacientes com ITB alto. Achados similares foram tamb&#233;m descritos por Ono e cols.<sup>10</sup> e O'Hare e cols.<sup>17</sup>. Em nosso estudo, o risco ajustado de apresentar ITB alto &gt;1,3 foi 4,4 vezes mais alto no sexo masculino, quando comparado ao feminino. As raz&#245;es para tal diferen&#231;a n&#227;o s&#227;o claras e merecem investiga&#231;&#227;o futura. </p>
    <p>Nosso estudo apresenta limita&#231;&#245;es. Como &#233; um estudo observacional, uma rela&#231;&#227;o causal entre inflama&#231;&#227;o e ITB reduzido n&#227;o pode ser estabelecida. Outra limita&#231;&#227;o foi o fato de termos realizado apenas uma &#250;nica medida da PCR, apesar de informa&#231;&#245;es anteriores de que esse par&#226;metro pode apresentar instabilidade ao longo do tempo, refletindo mudan&#231;as transit&#243;rias no estado inflamat&#243;rio<sup>25</sup>. </p>
    <p>Em conclus&#227;o, o presente estudo avaliou um grande n&#250;mero de pacientes em HD de manuten&#231;&#227;o a fim de analisar a associa&#231;&#227;o entre os fatores de risco tradicionais e n&#227;o-tradicionais para doen&#231;a cardiovascular e &#237;ndice tornozelo-bra&#231;o. Diabetes estava associada com &#237;ndice tornozelo-bra&#231;o alto e baixo. Idade mais avan&#231;ada e inflama&#231;&#227;o estavam associadas com o risco de apresentar &#237;ndice tornozelo-bra&#231;o baixo, enquanto o dist&#250;rbio mineral &#243;sseo estava associado com &#237;ndice tornozelo-bra&#231;o alto. </p>
    <p>
      <fn id="nt" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Jocemir Ronaldo Lugon </p>
        <p> Rua Haddock Lobo 369/309 &#150; Tijuca </p>
        <p> 20260-131 - Rio de Janeiro, RJ &#150; Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="jocerl@huap.uff.br">jocerl@huap.uff.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 16/08/10; revisado recebido em 20/10/10; aceito em 27/10/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Foley RN, Parfrey PS, Sarnak M. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl. 3):S112-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical epidemiology of cardiovascular disease in chronic renal disease</article-title>
          <source>Am J Kidney Dis.</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>S112</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Sarnak</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocao MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58(1):353-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients</article-title>
          <source>Kidney Int</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>353</fpage>
          <lpage>62</lpage>
          <issue>1</issue>
          <volume>58</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cheung</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Sarnak</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dwyer</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Heyka</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Rocao</surname>
              <given-names>MV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31(4):601-17.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study</article-title>
          <source>Am J Kidney Dis</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>601</fpage>
          <lpage>17</lpage>
          <issue>4</issue>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Block</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Hulbert-Shearon</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Port</surname>
              <given-names>FK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-18.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mineral metabolism, mortality, and morbidity in maintenance hemodialysis</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2208</fpage>
          <lpage>18</lpage>
          <issue>8</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Block</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Klassen</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Lazarus</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ofsthun</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lowrie</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Chertow</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12(10):2131-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2131</fpage>
          <lpage>8</lpage>
          <issue>10</issue>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ganesh</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Stack</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Hulbert-Shearon</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Port</surname>
              <given-names>FK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35(3):469-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>C-reactive protein predicts all cause and cardiovascular mortality in hemodialysis patients</article-title>
          <source>Am J Kidney Dis</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>469</fpage>
          <lpage>76</lpage>
          <issue>3</issue>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yeun</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Mantadilok</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kaysen</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Fishbane S, Youn S, Kowalski EJ, Frei GL. Ankle-arm blood pressure index as a marker for atherosclerotic vascular diseases in hemodialysis patients. Am J Kidney Dis. 1995;25(1):34-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ankle-arm blood pressure index as a marker for atherosclerotic vascular diseases in hemodialysis patients</article-title>
          <source>Am J Kidney Dis</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>34</fpage>
          <lpage>9</lpage>
          <issue>1</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fishbane</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Youn</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kowalski</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Frei</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Rajagopalan S, Dellegrottaglie S, Furnis AL, Gillespie BW, Satayathum S, Lameire N, et al. Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation. 2006; 114(18):1914-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1914</fpage>
          <lpage>22</lpage>
          <issue>18</issue>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rajagopalan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dellegrottaglie</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Furnis</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Gillespie</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Satayathum</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lameire</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Fishbane S, Youn S, Flaster E, Adam G, Maesaka JK. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis. 1996;27(5):668-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients</article-title>
          <source>Am J Kidney Dis</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>668</fpage>
          <lpage>72</lpage>
          <issue>5</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fishbane</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Youn</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Flaster</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Adam</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Maesaka</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Ono K, Tsuchida A, Kawai H, Matsuo H, Wakamatsu R, Maezawa A, et al. Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol. 2003;14(6):1591-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1591</fpage>
          <lpage>8</lpage>
          <issue>6</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ono</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuchida</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kawai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsuo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wakamatsu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Maezawa</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol. 1988;17(2):248-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys</article-title>
          <source>Int J Epidemiol</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>248</fpage>
          <lpage>54</lpage>
          <issue>2</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fowkes</surname>
              <given-names>FG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Donnelly R, Hinwood D, London NJ, ABC of arterial and venous disease: noninvasive methods of arterial and venous assessment. BMJ. 2000;320(7236):698-701.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ABC of arterial and venous disease: noninvasive methods of arterial and venous assessment</article-title>
          <source>BMJ</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>698</fpage>
          <lpage>701</lpage>
          <issue>7236</issue>
          <volume>320</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Donnelly</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hinwood</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>London</surname>
              <given-names>NJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Pollak JF, et al Ankle-arm index as a predictor of cardiovascular disease and mortality in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 1999;19(3):538-45.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ankle-arm index as a predictor of cardiovascular disease and mortality in the cardiovascular health study</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>538</fpage>
          <lpage>45</lpage>
          <issue>3</issue>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Newman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Shemanski</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Manolio</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Cushman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mittelmark</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pollak</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA. 1993;270(4):465-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Decreased ankle/arm blood pressure index and mortality in elderly women</article-title>
          <source>JAMA</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>465</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>270</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vogt</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Cauley</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Newman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Kuller</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Hulley</surname>
              <given-names>SB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Newman AB, Sutton-Tyrel K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA. 1993;270(4):487-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index</article-title>
          <source>JAMA</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>487</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>270</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Newman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Sutton-Tyrel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vogt</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Kuller</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Orchard TJ, Strandness DE Jr. Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by the American Diabetes and the American Heart Association September 1820, 1992 New Orleans, Louisiana. Circulation. 1993;88(2):819-28.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by the American Diabetes and the American Heart Association September 18-20, 1992 New Orleans, Louisiana</article-title>
          <source>Circulation</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>819</fpage>
          <lpage>28</lpage>
          <issue>2</issue>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Orchard</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Strandness Jr</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. O'Hare AM, Katz R, Shlipak MG, Cushman M, Newman AB. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation. 2006;113(3):388-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>388</fpage>
          <lpage>93</lpage>
          <issue>3</issue>
          <volume>113</volume>
          <person-group person-group-type="author">
            <name>
              <surname>O'Hare AM</surname>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shlipak</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Cushman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Newman</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>973</fpage>
          <lpage>9</lpage>
          <issue>14</issue>
          <volume>336</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ridker</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Cushman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stampfer</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Tracy</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Hennekens</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648-58.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Inflammation enhances cardiovascular risk and mortality in hemodialysis patients</article-title>
          <source>Kidney Int</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>648</fpage>
          <lpage>58</lpage>
          <issue>2</issue>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zimmermann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Herrlinger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pruy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Metzger</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wanner</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009;205(1):255-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey</article-title>
          <source>Atherosclerosis</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>255</fpage>
          <lpage>60</lpage>
          <issue>1</issue>
          <volume>205</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kendrick</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Targher</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Smits</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chonchol</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11(3):315-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis</article-title>
          <source>Hemodial Int</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>315</fpage>
          <lpage>21</lpage>
          <issue>3</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Del Valle</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Negri</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Aguirre</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fradinger</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zanchetta</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5(5):905-1.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters</article-title>
          <source>Clin J Am Soc Nephrol</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>905</fpage>
          <lpage>1</lpage>
          <issue>5</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Matias</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Jorge</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Borges</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aires</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Amaral</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Jaar BG, Plantinga LC, Astor BC, Fink NE, Longenecker C, Tracy RP, et al. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv Chronic Kidney Dis. 2007;14(3):304-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients</article-title>
          <source>Adv Chronic Kidney Dis</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>304</fpage>
          <lpage>13</lpage>
          <issue>3</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jaar</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Plantinga</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Astor</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Longenecker</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tracy</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):291-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States</article-title>
          <source>Am J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>291</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nissenson</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Batlle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Coyne</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Trout</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Warnock</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Dummer CD, Thom&#233; FS, Veronese FV. Doen&#231;a renal cr&#244;nica, inflama&#231;&#227;o e aterosclerose: novos conceitos de um velho problema. Rev Assoc Med Bras. 2007;53(5):446-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Doen&#231;a renal cr&#244;nica, inflama&#231;&#227;o e aterosclerose: novos conceitos de um velho problema</article-title>
          <source>Rev Assoc Med Bras</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>446</fpage>
          <lpage>50</lpage>
          <issue>5</issue>
          <volume>53</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dummer</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Thom&#233;</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Veronese</surname>
              <given-names>FV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Association of ankle-arm index with inflammation and mineral bone disorder in hemodialysis patients</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Reduced ankle-arm index (AAI), inflammation and mineral bone disorder (MBD) are all associated with increased risk of death and cardiovascular complications in patients on hemodialysis (HD), but the association between them deserves clarification. OBJECTIVE: To evaluate the association between abnormal AAI with MBD and inflammation in patients on HD. METHODS: This was a cross-sectional analysis of 478 patients on hemodialysis for at least one year. The AAI was evaluated using a portable Doppler and mercury column manometer. Patients were divided into 3 groups, according to AAI (low: &lt;0.9, normal: 0.9 to 1.3, and high: &gt;1.3). C-reactive protein measurement was used as an inflammatory marker, whereas MBD was evaluated by calcium, phosphorus and intact parathyroid hormone levels. RESULTS: Participants were 54 (18 to 75) years old, 56% males, 17% diabetics, and had been on hemodialysis for a mean of 5 (1 to 35) years. The prevalence of low, normal and high AAI was 26.8%, 64.6% and 8.6%, respectively. Using a backward conditional logistic regression model, age (p&lt;0.001), diabetes (p= 0.001), and C-reactive protein levels &gt;6 mg/L (p= 0.006) were associated with the presence of low AAI, whereas male gender (p&lt;0.001), diabetes (p= 0.001) and elevated calcium x phosphorus product (p= 0.026) were associated with high AAI. CONCLUSION: In patients on hemodialysis, the presence of diabetes was associated with both low and high AAI. The risk of having low AAI seems to be increased by aging and inflammation, whereas BMD was associated with high AAI.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Ankle brachial index</kwd>
        <kwd>inflammation</kwd>
        <kwd>calcinosis</kwd>
        <kwd>renal dialysis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p><undefined id="tx-body2"/>Association of ankle-arm index with inflammation and mineral bone disorder in hemodialysis patients</p>
      <p>
        <bold>Jair B. Miguel<sup>I,II</sup>; Jorge P. Strogoff de Matos<sup>I</sup>; Frederico Ruzany<sup>III</sup>; Claudia S. Miguel<sup>II</sup>; Sebasti&#227;o J. S. Miguel<sup>II</sup>; Luiz T. Naveiro<sup>I</sup>; Jocemir R. Lugon<sup>I</sup></bold>
      </p>
      <p><sup>I</sup>Divis&#227;o de Nefrologia, Departmento de Medicina, Universidade Federal Fluminense, Niteroi, RJ - Brasil</p>
      <p><sup>II</sup>Clinefron, Cl&#237;nica de Doen&#231;as Renais, Santo Ant&#244;nio de P&#225;dua, RJ - Brasil</p>
      <p><sup>III</sup>CDR, Cl&#237;nica de Doen&#231;as Renais, Rio de Janeiro, RJ - Brazil</p>
      <p>Mailing Address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Reduced ankle-arm index (AAI), inflammation and mineral bone disorder (MBD) are all associated with increased risk of death and cardiovascular complications in patients on hemodialysis (HD), but the association between them deserves clarification.</p>
      <p><bold>OBJECTIVE:</bold> To evaluate the association between abnormal AAI with MBD and inflammation in patients on HD.</p>
      <p><bold>METHODS:</bold> This was a cross-sectional analysis of 478 patients on hemodialysis for at least one year. The AAI was evaluated using a portable Doppler and mercury column manometer. Patients were divided into 3 groups, according to AAI (low: &lt;0.9, normal: 0.9 to 1.3, and high: &gt;1.3). C-reactive protein measurement was used as an inflammatory marker, whereas MBD was evaluated by calcium, phosphorus and intact parathyroid hormone levels.</p>
      <p><bold>RESULTS:</bold> Participants were 54 (18 to 75) years old, 56% males, 17% diabetics, and had been on hemodialysis for a mean of 5 (1 to 35) years. The prevalence of low, normal and high AAI was 26.8%, 64.6% and 8.6%, respectively. Using a backward conditional logistic regression model, age (p&lt;0.001), diabetes (p= 0.001), and C-reactive protein levels <underline>&gt;</underline>6 mg/L (p= 0.006) were associated with the presence of low AAI, whereas male gender (p&lt;0.001), diabetes (p= 0.001) and elevated calcium x phosphorus product (p= 0.026) were associated with high AAI.</p>
      <p><bold>CONCLUSION:</bold> In patients on hemodialysis, the presence of diabetes was associated with both low and high AAI. The risk of having low AAI seems to be increased by aging and inflammation, whereas BMD was associated with high AAI.</p>
      <p><bold>Keywords:</bold> Ankle brachial index; inflammation; calcinosis; renal dialysis.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>The mortality rate among end-stage renal disease (ESRD) patients is excessively high and the main cause of death is cardiovascular disease (CVD)<sup>1</sup>. This burden of CVD has been attributed to both traditional and nontraditional risk factors, which are related to chronic kidney disease and/or dialysis procedure. Age, diabetes mellitus and smoking are traditional factors also applicable to dialysis patients<sup>2</sup>. Among nontraditional risk factors, mineral bone disorder (MBD), including high serum phosphorus, high calcium x phosphorus product and extreme intact parathyroid hormone (i-PTH) serum levels have all been associated with increased cardiovascular mortality risk<sup>3-5.</sup> Another nontraditional risk factor for cardiovascular death is microinflammation, usually assessed by C-reactive protein (CRP) serum levels.<sup>6</sup></p>
      <p>In addition to coronary artery disease and cerebrovascular disease, peripheral arterial disease (PAD) is also highly prevalent among dialysis patients and its presence has been associated with high mortality<sup>7-10</sup>. The ankle-arm index (AAI) has been used as a diagnostic tool for PAD<sup>11</sup>. This index is based on the fact that systolic blood pressure in the legs is usually equal to or slightly higher than in the upper limbs in healthy individuals. In the presence of an arterial stenosis, a reduction in pressure occurs distal to the lesion<sup>12</sup>. When angiography was used as a gold standard, AAI ratio &lt;0.9 was found to have high sensitivity and specificity when diagnosing PAD<sup>11</sup>. In addition, low AAI has a strong correlation with arterial disease in other sites and has been found to be a good predictor of mortality in the general population<sup>7-10,13,14</sup>.</p>
      <p>Both low and high AAI have been found to be strong predictors of death among hemodialysis patients<sup>7-10,13,14</sup> and it is plausible to think that high AAI in ESRD patients could be due to vascular calcification and arterial wall stiffness associated with MBD. </p>
      <p>The aim of this study was to evaluate the association of low and high AAI values in patients on hemodialysis with several nontraditional cardiovascular risk factors, namely, inflammation and MBD.</p>
      <p>
        <bold>Materials and methods</bold>
      </p>
      <p>This is a cross-sectional multicenter study, performed at six dialysis facilities in Rio de Janeiro state, Brazil. The study was approved by the local Ethics Committee and all the patients signed the informed consent. The imaging studies and AAI measurements were taken between March 2006 and September 2007. All patients aged 18 to 75 years, who had been on hemodialysis for at least 12 months, were approached for enrollment. Exclusion criteria were: neoplasia diagnosis, presence of a positive anti-HIV test, atrial fibrillation, bilateral lower-limb amputation and dementia.</p>
      <p>
        <bold>The ankle-arm index</bold>
      </p>
      <p>Patients were evaluated once to obtain the AAI. Measurement was accomplished before hemodialysis session, after 5 minutes in supine position. The AAI, defined as the ratio of ankle-to-arm systolic blood pressure, was measured by 3 trained observers (one physician and two medical students) based on the information that interobserver and intraobserver variability for Doppler blood pressure measurement is negligible<sup>7,15</sup>. In lower limbs, tibial posterior arteries were used, since the <italic>dorsalis pedis</italic> artery is congenitally absent in 4-12% of the population<sup>11</sup>. Systolic blood pressure was measured twice at each site, in rapid and alternate succession, to obtain a mean value. Standard blood pressure arm cuffs connected to a mercury column were applied to the arm and to each ankle (with the lower end of the bladder just above the malleoli). After palpation of the arteries, ultrasound gel was applied, and a Doppler stethoscope (10 MHz, Super Dupplex, Huntleigh Technology Inc., Manalapan NJ, USA) was used to assess systolic blood pressure. Systolic blood pressure in the upper limb was measured on the brachial artery of the arm contralateral to the vascular access. To calculate AAI, the lowest mean from the ankles was divided by the mean in the arm.<sup>16</sup></p>
      <p>To evaluate the relationship between AAI and demographics, clinical and laboratory data, the population was divided into three groups according to AAI values: low AAI group (&lt;0.9), normal AAI group (0.9 to 1.3) and high AAI group (&gt;1.3).</p>
      <p>
        <bold>Demographic, clinical and laboratory data</bold>
      </p>
      <p>Demographics and clinical data were derived from both a structured clinical interview and a database used in all six dialysis units. These data included gender, age, ethnicity, time on dialysis, primary renal disease, vascular access, current smoking (yes/no), and use of medications (calcium acetate, calcium carbonate, calcitriol, sevelamer and erythropoietin). Comorbidities were defined as follows: Hypertension (pre-dialysis systolic BP <underline>&gt;</underline>140 mmHg and/or diastolic pressure <underline>&gt;</underline>90 mmHg and/or use of antihypertensive medications); coronary artery disease (exertion angina, current use of coronary vasodilator, past myocardial infarction, and coronary artery bypass surgery or angioplasty); stroke sequelae; PAD (current use of peripheral vasodilator, past lower limb artery bypass surgery or angioplasty or nontraumatic lower limb amputation); diabetes mellitus (diabetic nephropathy as the primary renal disease or clinical diagnosis after renal replacement therapy start); parathyroidectomy; and hepatitis C seropositivity.</p>
      <p>Hemoglobin, creatinine, and equilibrated Kt/V (eKt/V) values were defined by calculating the mean of the last three determinations nearest to the AAI measurement. To better estimate the impact of MBD on findings, cumulative exposure was assessed through calculation of the mean of all values for serum calcium, phosphorus and intact parathyroid hormone (i-PTH) measurements along a 36-month period, just before AAI evaluation or since hemodialysis initiation for patients on renal replacement therapy for less than 3 years. Calcium and phosphorus serum levels were measured on a monthly basis and i-PTH every six months. Routine blood analyses were performed in the same laboratory. An ultra-sensitive immunoturbidimetric assay for C-reactive protein (CRP) was specifically employed for the study and the values shown were determined by the time AAI was measured.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Continuous variables were presented as mean &#177; SD if data followed a normal distribution and as median and range if data distribution was non-Gaussian. Categorical variables were shown as frequencies. Differences among AAI groups were assessed by one-way ANOVA complemented by Bonferroni test or by Kruskal-Wallis ANOVA complemented by Dunn test as appropriate. Analysis of the frequencies was performed by Fisher's exact test. The association between variables and the risk of presenting low AAI was studied by backward conditional logistic regression. Age, gender, diabetes, smoking, time on dialysis, serum albumin, CRP, calcium, phosphorus, calcium ' phosphorus product and i-PTH were included in the initial step. The same analysis was performed to assess the variables associated with the risk of having high AAI. P&lt;0.05 were considered significant. The software SPSS, version 17.0 was used for the statistical analysis.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Of a total of 1170 ESRD patients on maintenance hemodialysis in the six facilities, 478 patients were enrolled in the study. General characteristics of patients are listed in <xref ref-type="table" rid="tab01-body2">Table 1</xref>. Median age was 53.6 (18 to 75) years, 56% were males, 16.9% diabetics, and 50.6% had hypertension as the primary renal disease. Median time on dialysis was 59 (12 to 427) months, with 27% of patients on dialysis for less than 3 years. Values of selected laboratory parameters were: eKt/V 1.51&#177;0.40; hemoglobin 11.4&#177;1.6 g/dl; serum albumin 3.8&#177;0.3 g/ dl; CRP 4.7 (0.1 - 150) mg/l; ion calcium 4.6&#177;0.3 mg/dl; phosphorus 5.4&#177;1.2 mg/dl; and i-PTH 370 (10 - 2500) pg/ml.</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt01-en.jpg"/></table-wrap>
      <p>The prevalence of low, normal and high AAI was 26.8%, 64.6% and 8.6%, respectively. <xref ref-type="table" rid="tab02-body2">Table 2</xref> shows the characteristics of each AAI group.</p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt02-en.jpg"/></table-wrap>
      <p>Patients in the low AAI group were significantly older than those in the normal and high AAI groups. Male gender prevailed in the high AAI group, when compared to the low and normal ones. The prevalence of diabetes, PAD and nontraumatic amputation was significantly lower in the normal AAI group, when compared to both the low and high AAI groups. Coronary artery disease and stroke sequelae were more frequent in the low AAI group than in the normal AAI group. No difference was observed regarding blood pressure or pulse pressure measurements among AAI groups (data not shown).</p>
      <p>The laboratory findings by AAI group are shown in <xref ref-type="table" rid="tab03-body2">Table 3</xref>. The low AAI group presented higher CRP and lower serum albumin than the normal AAI group. Serum creatinine was lower in the low AAI group than in both the normal and high AAI groups. The high AAI group presented increased serum phosphorus levels and calcium x phosphorus product, when compared to the normal and high AAI groups. The high AAI group also presented increased i-PTH levels compared to the low AAI group.</p>
      <table-wrap id="tab03-body2">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt03-en.jpg"/></table-wrap>
      <p>In the regression analysis, only age, diabetes and elevated CRP were significantly associated with the risk of presenting low AAI (<xref ref-type="table" rid="tab04-body2">Table 4</xref>), whereas the variables associated with the risk of presenting high AAI were male gender, diabetes and elevated calcium ' phosphorus product (<xref ref-type="table" rid="tab05-body2">Table 5</xref>).</p>
      <table-wrap id="tab04-body2">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt04-en.jpg"/></table-wrap>
      <table-wrap id="tab05-body2">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt05-en.jpg"/></table-wrap>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>In the present study, a high prevalence of abnormal AAI, mostly low AAI, was seen in patients on maintenance hemodialysis. AAI measurement is an easy, reliable and non-invasive test, which is a marker of atherosclerotic vascular disease as well as a predictor of mortality in the general population and patients on hemodialysis<sup>9,10,13,14</sup>.</p>
      <p>CVD has been identified as the main cause of death in dialysis patients<sup>1</sup>. Both, traditional and nontraditional risk factors related to chronic kidney disease and/or dialysis procedure are involved in this process. Among nontraditional CVD risk factors, BMD, inflammation and time on dialysis have been widely explored<sup>3-6</sup>. However, a link between abnormal AAI and such nontraditional risk factors is lacking.</p>
      <p>Underscoring the role of AAI as a surrogate marker of generalized atherosclerosis, we found that the low AAI group had higher prevalence of CVD.</p>
      <p>As expected, diabetes was found to be associated with increased risk of low AAI. In the present study, diabetes was also associated with increased risk of high AAI. This could be accounted for by the greater prevalence of vascular calcification in such patients, which promotes arterial stiffness and higher blood pressure in lower limbs<sup>10</sup>.</p>
      <p>The predominance of older patients in the low AAI group in our study is in agreement with previous studies evaluating general and hemodialysis populations<sup>9,10,13,14</sup>. We found that the risk of having low AAI almost doubles for each additional decade. This finding reinforces age as a traditional risk factor for PAD in hemodialysis patients.</p>
      <p>The patients with low AAI presented higher CRP levels and lower serum albumin and creatinine levels. These are not unexpected findings, as the association of malnutrition and inflammation with atherosclerotic disease and PAD, in general and hemodialysis populations, is well-known<sup>17-19</sup>. In the regression analysis, a CRP value <underline>&gt;</underline>6 mg/L was the sole laboratory variable associated with the risk of presenting low AAI. Patients on hemodialysis usually present much higher CRP levels than those seen in general population. Thus, CRP level <underline>&gt;</underline>6 mg/dL was a pre-specified definition of abnormality adopted by the dialysis facilities participating in the present study.</p>
      <p>Serum phosphate levels were higher in patients with high AAI, probably reflecting its role in vascular calcification, as calcified arteries are stiffer and present a higher blood pressure<sup>10</sup>. No difference in serum calcium levels, according to AAI classification, was found. In the regression analysis, the only laboratory variable associated with the risk of presenting high AAI was the calcium ' phosphorus product. No BMD marker was found to be associated with the risk of having low AAI. It should be stressed that in the current study, we used the means of calcium, phosphate and i-PTH measurements obtained throughout a 36-month period preceding AAI evaluation or since initiation of renal replacement therapy for those less than 3 years on hemodialysis. Vitamin D deficiency has been recognized as a nontraditional risk factor for atherosclerosis and adverse cardiovascular outcomes<sup>20</sup>. The deficiency of both 25-hydroxyvitamin D and its active form, 1,25-dihydroxyvitamin D, is highly prevalent in patients on hemodialysis<sup>21,22</sup>. We believe that some vascular abnormalities seen in our study could be at least partially attributed to vitamin D deficiency. As we could not measure serum vitamin D, this issue was not addressed in our study.</p>
      <p>No association was detected between time on dialysis and the risk of presenting low or high AAI. Accordingly, PAD does not seem to be a complication of renal failure and/or the supportive therapy, but a consequence of other conditions, mainly aging and diabetes. Similar finding was demonstrated by Cheung <italic>et al.</italic><sup>10</sup>, but not by Rajagopalan <italic>et al</italic>.<sup>23</sup>, who found a positive correlation between time on dialysis and PAD.</p>
      <p>In our analysis, hypertension was not associated with low or high AAI, an observation also reported by Cheung <italic>et al</italic>.<sup>2 </sup>and Jaar <italic>et al</italic>.<sup>24</sup>, Hypertension is widely present among hemodialysis patients, with a prevalence that may reach 80% in some populations, making detection of its effect upon a specific subgroup hard to demonstrate<sup>25</sup>. It should be stressed that Rajagopalan <italic>et al</italic>.<sup>23</sup> found a positive association between hypertension and PAD illustrating that data, in this regard, are not consensual.</p>
      <p>Surprisingly, we found no association between smoking and the risk of abnormal AAI. Perhaps, the low prevalence of smoking in our population could have mitigated such effect. The association between smoking and PAD in hemodialysis patients was demonstrated by Cheung <italic>et al</italic>.<sup>2</sup> and Rajagopalan <italic>et al</italic>.<sup>23</sup>, but not by Ono <italic>et al</italic>.<sup>10</sup>.</p>
      <p>We found a predominance of males among patients with high AAI. Similar finding was also described by Ono <italic>et al</italic>.<sup>10</sup> and O'Hare <italic>et al</italic>.<sup>17</sup>. In our study, the adjusted risk of presenting high AAI &gt;1.3 was 4.4-fold higher for males compared to females. The reasons for such difference are not clear and deserve further investigation. </p>
      <p>Our study carries limitations. As it is an observational study, a causal relationship between inflammation and reduced AAI cannot be established. Another limitation is that we resorted to a single measurement of CRP despite previous information that this parameter may exhibit some instability along time, reflecting transient changes in inflammatory state<sup>26</sup>.</p>
      <p>In conclusion, the current study assessed a large number of patients on maintenance hemodialysis in order to evaluate the association between traditional and nontraditional risk factors for cardiovascular disease and ankle-arm index. Diabetes was associated with both low and high ankle-arm index. Aging and inflammation were associated with the risk of presenting low ankle-arm index, whereas bone metabolism disorder was associated with high ankle-arm index.</p>
      <p>
        <bold>ReferenceS</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Asociaci&#243;n del &#237;ndice Tobillo-Brazo con la inflamaci&#243;n y trastornos minerales &#243;seos en pacientes en hemodi&#225;lisis</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El &#237;ndice tobillo-brazo (ITB) reducido, la inflamaci&#243;n y el trastorno mineral &#243;seo (TMO) se asocian con mayor riesgo de muerte y complicaciones cardiovasculares en pacientes sometidos a hemodi&#225;lisis (HD), pero la relaci&#243;n entre estos factores debe ser aclarada. Objetivos: Evaluar la asociaci&#243;n entre el ITB anormal la TMO con inflamaci&#243;n en paciente en HD. M&#201;TODOS: Este an&#225;lisis transversal evalu&#243; a 478 pacientes en HD durante al menos 1 a&#241;o. El ITB se midi&#243; con un Doppler port&#225;til y man&#243;metro de columna de mercurio. Los pacientes fueron divididos en tres grupos, de acuerdo al ITB (bajo: &lt; 0,9, normal: 0,9 a 1,3, y alto: &gt; 1,3). Las mediciones de prote&#237;na C-reactiva se utilizaron como marcador inflamatorio, mientras que la TMO se evalu&#243; a trav&#233;s de los niveles de calcio, f&#243;sforo y hormona paratiroidea intacta (iPTH). RESULTADOS: Los participantes ten&#237;an 54 (18-75) a&#241;os, el 56% eran del sexo masculino, el 17% eran diab&#233;ticos y estaban se encontraban en HD por 5 (1 a 35) a&#241;os. La prevalencia de ITB bajo, normal y alto ITB fue de un 26,8%, un 64,6% y un 8,6% respectivamente. Al utilizar un modelo de regresi&#243;n log&#237;stica condicional con el procedimiento backward (hacia atr&#225;s), diabetes (p &lt; 0,001), y niveles de prote&#237;na C-reactiva &gt; 6 mg/l (p = 0,006) estaban asociados con la presencia de ITB bajo, mientras que el sexo masculino (p &lt; 0,001), diabetes (p = 0,001) y producto calcio x f&#243;sforo elevado (p = 0,026) estaban asociados con ITB alto. CONCLUSI&#211;N: En los pacientes en HD, la presencia de la diabetes estaba asociada con ITB alto y bajo. El riesgo de tener ITB bajo parece aumentar con la edad y la inflamaci&#243;n, mientras que la TMO estaba asociada con ITB alta. (Arq Bras Cardiol 2011;96(5):405-410)</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>&#205;ndice tobillo-brazo</kwd>
        <kwd>inflamaci&#243;n</kwd>
        <kwd>calcinosis</kwd>
        <kwd>di&#225;lisis renal</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="topo-body3"/>Asociaci&#243;n del &#237;ndice Tobillo-Brazo con la inflamaci&#243;n y trastornos minerales &#243;seos en pacientes en hemodi&#225;lisis</p>
      <p>
        <bold>Jair B. Miguel<sup>I,II</sup>; Jorge P. Strogoff de Matos<sup>I</sup>; Frederico Ruzany<sup>III</sup>; Claudia S. Miguel<sup>II</sup>; Sebasti&#227;o J. S. Miguel<sup>II</sup>; Luiz T. Naveiro<sup>I</sup>; Jocemir R. Lugon<sup>I</sup></bold>
      </p>
      <p><sup>I</sup>Divis&#227;o de Nefrologia, Departamento de Medicina, Universidade Federal Fluminense, Niter&#243;i, RJ - Brasil</p>
      <p><sup>II</sup>Clinefron, Cl&#237;nica de Doen&#231;as Renais, Santo Ant&#244;nio de P&#225;dua, RJ - Brasil</p>
      <p><sup>III</sup>CDR, Cl&#237;nica de Doen&#231;as Renais, Rio de Janeiro, RJ - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> El &#237;ndice tobillo-brazo (ITB) reducido, la inflamaci&#243;n y el trastorno mineral &#243;seo (TMO) se asocian con mayor riesgo de muerte y complicaciones cardiovasculares en pacientes sometidos a hemodi&#225;lisis (HD), pero la relaci&#243;n entre estos factores debe ser aclarada.</p>
      <p><bold>Objetivos:</bold> Evaluar la asociaci&#243;n entre el ITB anormal la TMO con inflamaci&#243;n en paciente en HD.</p>
      <p><bold>M&#201;TODOS:</bold> Este an&#225;lisis transversal evalu&#243; a 478 pacientes en HD durante al menos 1 a&#241;o. El ITB se midi&#243; con un Doppler port&#225;til y man&#243;metro de columna de mercurio. Los pacientes fueron divididos en tres grupos, de acuerdo al ITB (bajo: &lt; 0,9, normal: 0,9 a 1,3, y alto: &gt; 1,3). Las mediciones de prote&#237;na C-reactiva se utilizaron como marcador inflamatorio, mientras que la TMO se evalu&#243; a trav&#233;s de los niveles de calcio, f&#243;sforo y hormona paratiroidea intacta (iPTH).</p>
      <p><bold>RESULTADOS:</bold> Los participantes ten&#237;an 54 (18-75) a&#241;os, el 56% eran del sexo masculino, el 17% eran diab&#233;ticos y estaban se encontraban en HD por 5 (1 a 35) a&#241;os. La prevalencia de ITB bajo, normal y alto ITB fue de un 26,8%, un 64,6% y un 8,6% respectivamente. Al utilizar un modelo de regresi&#243;n log&#237;stica condicional con el procedimiento <italic>backward</italic> (hacia atr&#225;s), diabetes (p &lt; 0,001), y niveles de prote&#237;na C-reactiva <underline>&gt;</underline> 6 mg/l (p = 0,006) estaban asociados con la presencia de ITB bajo, mientras que el sexo masculino (p &lt; 0,001), diabetes (p = 0,001) y producto calcio x f&#243;sforo elevado (p = 0,026) estaban asociados con ITB alto.</p>
      <p><bold>CONCLUSI&#211;N:</bold> En los pacientes en HD, la presencia de la diabetes estaba asociada con ITB alto y bajo. El riesgo de tener ITB bajo parece aumentar con la edad y la inflamaci&#243;n, mientras que la TMO estaba asociada con ITB alta. (Arq Bras Cardiol 2011;96(5):405-410)</p>
      <p><bold>Palabras clave:</bold> &#205;ndice tobillo-brazo, inflamaci&#243;n, calcinosis, di&#225;lisis renal.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La tasa de mortalidad en pacientes con enfermedad renal cr&#243;nica (ERC) terminal es muy alta y la causa principal de muerte es la enfermedad cardiovascular (ECV)<sup>1</sup>. Este impacto de la ECV ha sido atribuido a factores de riesgo tradicionales y no-tradicionales, que est&#225;n relacionados a enfermedad renal cr&#243;nica y/o procedimiento de di&#225;lisis. Edad, diabetes mellitus y tabaquismo son factores tradicionales tambi&#233;n aplicables a pacientes en di&#225;lisis<sup>2</sup>. Entre los factores de riesgo no-tradicionales, el trastorno mineral &#243;seo (TMO), incluidos altos niveles de f&#243;sforo, producto calcio x f&#243;sforo alto y niveles s&#233;ricos extremos de hormona paratiroidea intacta (iPTH) se vienen asociando al aumento del riesgo de mortalidad cardiovascular<sup>3-5</sup>. Otro factor de riesgo no-tradicional para muerte cardiovascular es la microinflamaci&#243;n, generalmente evaluada a trav&#233;s de los niveles s&#233;ricos de prote&#237;na C-reactiva (PCR)<sup>6</sup>. </p>
      <p>Adem&#225;s de la enfermedad arterial coronaria y la enfermedad cerebrovascular, la enfermedad arterial perif&#233;rica (EAP) es tambi&#233;n muy frecuente en pacientes en di&#225;lisis y su presencia se ha asociado con alta mortalidad <sup>7-10</sup>. El &#237;ndice tobillo-brazo (ITB) se viene utilizando como una herramienta diagn&#243;stica para la EAP<sup>11</sup>. El &#237;ndice est&#225; basado en el hecho de que la presi&#243;n arterial sist&#243;lica en las piernas es generalmente igual o levemente m&#225;s alta que en los miembros superiores de individuos sanos. En presencia de una estenosis arterial, una reducci&#243;n en la presi&#243;n se produce en la posici&#243;n distal lesi&#243;n<sup>12</sup>. Cuando la angiograf&#237;a se utilizaba como el patr&#243;n-oro, una raz&#243;n ITB &lt; 0.9 se considerada como de alta sensibilidad y especificidad en el diagn&#243;stico de EAP<sup>11</sup>. Adem&#225;s de esto, un ITB bajo presenta una fuerte correlaci&#243;n con la enfermedad arterial en otros sitios y se viene mostrando un buen predictor de mortalidad en la poblaci&#243;n en general<sup>7-10,13,14</sup>.</p>
      <p>Tanto el ITB bajo como el alto han estado mostrando fuertes predictores de muerte en pacientes en hemodi&#225;lisis (HD)<sup>7- 10,13,14</sup>. Es presumible considerar que un ITB alto en pacientes con DRC terminal puede ser debido a la calcificaci&#243;n vascular y rigidez de la pared arterial asociada con TMO.</p>
      <p>El objetivo de este estudio fue evaluar la asociaci&#243;n entre los valores de ITB de altas y bajas en los pacientes en HD con m&#250;ltiples factores de riesgo cardiovascular, no tradicionales, es decir, la inflamaci&#243;n y el TMO. </p>
      <p>
        <bold>Materiales y m&#233;todos</bold>
      </p>
      <p>Este es un corte transversal, multic&#233;ntrico realizado en seis cl&#237;nicas de di&#225;lisis en R&#237;o de Janeiro, Brasil. El estudio fue aprobado por el Comit&#233; de &#201;tica y todos los pacientes firmaron el consentimiento informado. Los estudios de im&#225;genes y mediciones de ITB se realizaron entre marzo de 2006 y septiembre de 2007. Todos los pacientes con edad de 18 a 75 a&#241;os, que estaban en HD durante 12 meses como m&#237;nimo, han sido invitados a participar del estudio. Los criterios de exclusi&#243;n fueron: diagn&#243;stico de neoplasia, presencia de positivo en la prueba del VIH, fibrilaci&#243;n auricular, amputaci&#243;n bilateral de miembros inferiores y la demencia. </p>
      <p>
        <bold>El &#237;ndice tobillo-brazo</bold>
      </p>
      <p>Los pacientes fueron evaluados una vez para obtener el &#237;ndice tobillo-brazo (ITB). Las mediciones se realizaron antes de la sesi&#243;n de HD, despu&#233;s de 5 minutos en la posici&#243;n supina. El ITB, que se define como la relaci&#243;n entre la presi&#243;n arterial sist&#243;lica del tobillo y del brazo, se midi&#243; por tres observadores entrenados (un m&#233;dico y dos estudiantes de Medicina), con base en la informaci&#243;n que la variabilidad interobservador y la intraobservador para la medici&#243;n de presi&#243;n arterial por Doppler es insignificante<sup>7,15</sup>. En los miembros inferiores, las arterias tibiales posteriores se utilizaron, considerando que la arteria <italic>dorsalis pedis</italic> est&#225; cong&#233;nitamente ausente en el 4-12% de la poblaci&#243;n<sup>11</sup>. La presi&#243;n arterial sist&#243;lica (PAS) se midi&#243; dos veces en cada sitio, en una sucesi&#243;n alternada y r&#225;pida, a fin de obtenerse un valor medio. Manguitos est&#225;ndar para medir la PA se aplicaron en el brazo y cada tobillo (con el extremo inferior de la pera colocada justo por encima de los mal&#233;olos). Despu&#233;s de la palpaci&#243;n de las arterias, se aplic&#243; gel de ultrasonido y un estetoscopio Doppler (10 MHz, Super Dupplex, Huntleigh Technology Inc., Manalapan NJ, EE.UU.) se utiliz&#243; para evaluar la PAS. La PAS en el miembro superior braquial se midi&#243; en el brazo contralateral al acceso vascular. Para el c&#225;lculo del ITB, lo m&#225;s bajo promedio de los tobillos se dividi&#243; por el promedio del brazo<sup>16</sup>. </p>
      <p>Para evaluar la relaci&#243;n entre el ITB y los datos demogr&#225;ficos, cl&#237;nicos y de laboratorio, la poblaci&#243;n se dividi&#243; en tres grupos de acuerdo a los valores del ITB: el grupo con ITB bajo (&lt; 0,9), el grupo con ITB normal (0,9 a 1,3) y grupo con ITB alto (&gt; 1.3).</p>
      <p>
        <bold>Datos demogr&#225;ficos, cl&#237;nicos y de laboratorio</bold>
      </p>
      <p>Los datos cl&#237;nicos y demogr&#225;ficos fueron obtenidos a trav&#233;s de una entrevista cl&#237;nica estructurada y el banco de datos utilizado en las seis cl&#237;nicas de di&#225;lisis. Estos datos incluyen el sexo, la edad, el origen &#233;tnico, la duraci&#243;n de la di&#225;lisis, la enfermedad renal primaria, el acceso vascular, el tabaquismo actual (s&#237;/no) y el uso de medicamentos (acetato de calcio, carbonato de calcio, calcitriol, sevelamer y eritropoyetina). Comorbilidades se definieron como: hipertensi&#243;n (PAS predialisis <underline>&gt;</underline> 140 mmHg y/o presi&#243;n arterial diast&#243;lica (PAD) <underline>&gt;</underline> 90 mmHg y/o uso de medicaciones antihipertensivas); enfermedad arterial coronaria (angina de esfuerzo, uso actual de vasodilatador coronario, infarto de miocardio previo y cirug&#237;a de revascularizaci&#243;n o angioplastia previas); secuelas de derrame; EAP (uso actual de vasodilatador perif&#233;rico, cirug&#237;a de revascularizaci&#243;n de miembro inferior o angioplastia o amputaci&#243;n no-traum&#225;tica de miembro inferior); diabetes mellitus (nefropat&#237;a diab&#233;tica como enfermedad renal primaria o diagn&#243;stico cl&#237;nico tras inicio de terapia de sustituci&#243;n renal) paratiroidectom&#237;a; y soropositividad para hepatitis C </p>
      <p>Valores de la hemoglobina, creatinina y Kt/V equilibrado (eKT/V) se definieron por el promedio de las tres &#250;ltimas mediciones m&#225;s cercanas de la medici&#243;n del ITB. Con el fin de analizar mejor el impacto de los resultados de la TMO en los hallazgos, la exposici&#243;n acumulativa se evalu&#243; mediante el c&#225;lculo de la media de todas las mediciones de los valores s&#233;ricos de calcio, f&#243;sforo y la hormona paratiroidea intacta (iPTH) en un per&#237;odo de 36 meses inmediatamente anterior a la evaluaci&#243;n del ITB o desde el inicio de la HD en pacientes sometidos a la terapia de sustituci&#243;n renal por menos de 3 a&#241;os. Los niveles s&#233;ricos de calcio y f&#243;sforo fueron medidos mensualmente, los niveles de iPTH, cada seis meses. Los an&#225;lisis de sangre de rutina se realizaron en el mismo laboratorio. Un ensayo inmunoturbidim&#233;trico de alta sensibilidad para prote&#237;na C-reactiva (PCR) se utiliza espec&#237;ficamente para el estudio y los valores indicados han sido determinados en el momento mismo que se midi&#243; el ITB.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Las variables continuas se presentaron como media &#177; desviaci&#243;n est&#225;ndar (DE), si los datos siguieran una distribuci&#243;n normal y como mediana y variaci&#243;n si la distribuci&#243;n de los datos fuese no-Gaussiana. Las variables categ&#243;ricas se muestran como frecuencias. Las diferencias entre los grupos ITB se evaluaron a trav&#233;s de la prueba ANOVA one-way, complementado con el test de Bonferroni o Kruskal-Wallis ANOVA complementando con la prueba de Dunn, en su caso. El an&#225;lisis de frecuencias se realiz&#243; mediante la prueba exacta de Fisher. La asociaci&#243;n entre las variables y el riesgo de tener ITB bajo se estudi&#243; mediante regresi&#243;n log&#237;stica condicional con t&#233;cnica <italic>backward</italic>. Se incluyeron en la fase inicial la edad, el sexo, la diabetes, el tabaquismo, la duraci&#243;n de la di&#225;lisis, la alb&#250;mina s&#233;rica, la PCR, el calcio, f&#243;sforo, el producto calcio-f&#243;sforo e iPTH. El mismo an&#225;lisis se realiz&#243; para evaluar las variables asociadas con el riesgo de presentar ITB alto. Un valor de p&lt; 0,05 fue considerado significativo. El software SPSS, versi&#243;n 17.0 se utiliz&#243; para el an&#225;lisis estad&#237;stico.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>De un total de 1.170 pacientes con ERC terminal en HD de mantenimiento en las seis cl&#237;nicas, 478 pacientes fueron incluidos en el estudio. Las caracter&#237;sticas generales de los pacientes se muestran en la <xref ref-type="table" rid="t1-body3">Tabla 1</xref>. La mediana de la edad era 53,6 (18 a 75) a&#241;os; el 56% de los pacientes eran del sexo masculino, el 16,9% eran diab&#233;ticos y el 50,6% ten&#237;an hipertensi&#243;n como enfermedad renal primaria. La mediana de duraci&#243;n de la di&#225;lisis fue de 59 (12 a 427) meses, con un 27% de los pacientes en di&#225;lisis por menos de 3 a&#241;os. Los valores de los par&#225;metros de laboratorio fueron seleccionados: eKt/V 1,51 &#177; 0,40; hemoglobina 11,4 &#177; 1,6 g/dl; albumina s&#233;rica 3,8 &#177; 0,3 g/dl; PCR 4,7 (0,1 - 150) mg/l; ion calcio 4,6 &#177; 0,3 mg/dl; f&#243;sforo 5,4 &#177; 1,2 mg/dl; e i-PTH 370 (10 a 2.500) pg/ml.</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt01-es.jpg"/></table-wrap>
      <p>Las prevalencias de ITB bajo, normal y alto fueron un 26,8%, un 64,6% y un 8,6% respectivamente. La <xref ref-type="table" rid="t2-body3">Tabla 2</xref> muestra las caracter&#237;sticas de cada grupo ITB.</p>
      <table-wrap id="t2-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt02-es.jpg"/></table-wrap>
      <p>Los pacientes en el grupo ITB bajo eran significativamente mayores que los ITB normal y ITB alto. El sexo masculino prevaleci&#243; en el grupo con ITB alto, cuando comparado a los grupos ITB normal y bajo. La prevalencia de la diabetes, EAP y la amputaci&#243;n no traum&#225;tica fueron significativamente m&#225;s bajas en el grupo ITB normal que en el grupo ITB alto. La enfermedad arterial coronaria (EAC) y la secuela de derrame fueron m&#225;s frecuentes en el grupo ITB que en el grupo con ITB normal. Ninguna diferencia se observ&#243; con relaci&#243;n a las mediciones de la presi&#243;n arterial o la presi&#243;n del pulso entre los grupos del ITB (datos no presentados). </p>
      <p>Los hallazgos de laboratorio por el grupo ITB se muestran en la <xref ref-type="table" rid="t3-body3">Tabla 3</xref>. El grupo con ITB bajo mostraba niveles m&#225;s altos de PCR y m&#225;s bajos de albumina s&#233;rica que el grupo con ITB normal. Los niveles de creatinina s&#233;rica eran menores en el grupo con ITB bajo en comparaci&#243;n con los grupos con ITB normal y alto. El grupo con ITB alto presentaba un incremento en los niveles de f&#243;sforo s&#233;rico y producto de calcio x f&#243;sforo, cuando comparados con aquellos con ITB normal y bajo. El grupo con ITB alto hab&#237;a aumentado los niveles de iPTH, cuando comparaci&#243;n con aquellos con ITB bajo.</p>
      <table-wrap id="t3-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt03-es.jpg"/></table-wrap>
      <p>En el an&#225;lisis de regresi&#243;n, s&#243;lo la edad, la diabetes y niveles altos de PCR se asociaron significativamente con el riesgo de presentar ITB bajo (<xref ref-type="table" rid="t4-body3">Tabla 4</xref>), mientras que las variables asociadas con el riesgo de tener baja ITB fueron el sexo masculino, la diabetes, y el producto calcio-f&#243;sforo elevado (<xref ref-type="table" rid="t5-body3">Tabla 5</xref>).</p>
      <table-wrap id="t4-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt04-es.jpg"/></table-wrap>
      <table-wrap id="t5-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0405-00031-gt05-es.jpg"/></table-wrap>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>En este estudio, la alta prevalencia de ITB anormal, en la mayor&#237;a ITB bajo, se observ&#243; en pacientes en HD de mantenimiento.</p>
      <p>La medici&#243;n del ITB es una prueba f&#225;cil, m&#233;todo confiable y no invasivo, que es un marcador de enfermedad vascular ateroscler&#243;tica, as&#237; como un predictor de mortalidad en la poblaci&#243;n en general y en pacientes HD<sup>9,10,13,14</sup>.</p>
      <p>Las enfermedades cardiovasculares han estado siendo se&#241;aladas como la causa principal de muerte en pacientes en di&#225;lisis<sup>1</sup>. Ambos factores de riesgo tradicionales y no tradicionales relacionados a la enfermedad renal cr&#243;nica y/0 procedimiento de di&#225;lisis est&#225;n implicados en este proceso. Entre los factores de riesgo de ECV no tradicionales, la EMO, inflamaci&#243;n y la duraci&#243;n de la di&#225;lisis vienen siendo ampliamente explorados<sup>3-6</sup>. Sin embargo, hace falta una relaci&#243;n entre el ITB anormal y dichos factores de riesgo no tradicionales. </p>
      <p>Haciendo hincapi&#233; en el papel del ITB como un marcador sustituto de la aterosclerosis generalizada, se observ&#243; que el grupo con ITB bajo ten&#237;a mayor prevalencia de ECV. </p>
      <p>Como era de esperar, se encontr&#243; que la diabetes se asoci&#243; con un mayor riesgo de bajo ITB. En este estudio, la diabetes tambi&#233;n se asoci&#243; con un incremento en el riesgo de ITB alto. Esto puede atribuirse a la mayor prevalencia de calcificaci&#243;n vascular en estos pacientes, que promueve la rigidez arterial y la presi&#243;n arterial m&#225;s alta en los miembros inferiores<sup>10</sup>. La predominancia de pacientes m&#225;s viejos en el grupo con ITB bajo en nuestro estudio est&#225; de acuerdo con los estudios anteriores que evaluaron las poblaciones en general y aquellas en HD<sup>9,10,13,14</sup>. Observamos que el riesgo de presentar ITB bajo es casi el doble para cada d&#233;cada adicional. Este hallazgo refuerza la edad como un factor de riesgo tradicional para la EAP en los pacientes en HD. </p>
      <p>Los pacientes con ITB bajo ten&#237;an niveles de PCR m&#225;s altos y m&#225;s bajos niveles s&#233;ricos m&#225;s bajos de alb&#250;mina y creatinina. Estos resultados no son inesperados, teniendo en cuenta que la asociaci&#243;n de la desnutrici&#243;n y la inflamaci&#243;n con la enfermedad aterosclerosis y la eAP, en las poblaciones en general y en HD, es bien conocida<sup>17-19</sup>. En el an&#225;lisis de regresi&#243;n, el nivel de PCR <underline>&gt;</underline> 6 mg/l fue la &#250;nica variable de laboratorio asociada con el riesgo de presentar ITB bajo. Pacientes en HD por lo general tienen niveles de PCR mucho mayor que los observados en la poblaci&#243;n en general. Por lo tanto, los niveles de PCR <underline>&gt;</underline> 6 mg/dl fue una definici&#243;n pre especificada de anormalidad adoptada por las cl&#237;nicas de di&#225;lisis que participaron en el estudio. </p>
      <p>El nivel de fosfato s&#233;rico fue mayor en los pacientes con ITB alto, probablemente como reflejo de su papel en la calcificaci&#243;n vascular, como las arterias calcificadas son m&#225;s r&#237;gidas y tienen m&#225;s presi&#243;n de la sangre elevada<sup>10</sup>. Ninguna diferencia se observ&#243; en los niveles s&#233;ricos de calcio de acuerdo con la clasificaci&#243;n del ITB. En el an&#225;lisis de regresi&#243;n, la &#250;nica variable de laboratorio asociada con el riesgo de tener ITB alto era el producto calcio-f&#243;sforo. Ning&#250;n marcador de TMO se asoci&#243; al riesgo con de tener ITB bajo. Cabe destacar que en el presente estudio, se utiliz&#243; el promedio de las mediciones de calcio, fosfato e iPTH llevadas a cabo durante un per&#237;odo de 36 meses antes de la evaluaci&#243;n del ITB o desde el comienzo de la terapia de reemplazo renal para los individuos en HD desde hace 3 a&#241;os. La deficiencia de vitamina D se la viene reconociendo como un factor de riesgo no tradicional para la aterosclerosis y desenlaces cardiovasculares adversos<sup>20</sup>. La deficiencia de 25-hidroxivitamina D y su forma activa 1,25-dihidroxivitamina D es altamente prevalente en pacientes y HD<sup>21,22</sup>. Nos parece que algunas anormalidades vasculares observadas en nuestro estudio podr&#237;an ser al menos parcialmente atribuidas a la deficiencia de vitamina D. Como no fue posible medir los niveles s&#233;ricos de vitamina D, esta cuesti&#243;n no se analiz&#243; en nuestro estudio.</p>
      <p>No se encontr&#243; asociaci&#243;n alguna entre la duraci&#243;n de la di&#225;lisis y el riesgo de tener alto o bajo ITB. Por lo tanto, la EAP no parece ser una complicaci&#243;n de la insuficiencia renal y/o terapia de apoyo, sino una consecuencia de otras condiciones, especialmente el envejecimiento de la diabetes. El hallazgo similar fue demostrado por Cheung et al<sup>10</sup>, pero no por Rajagopalan et al<sup>8</sup>, que observ&#243; una correlaci&#243;n positiva entre la duraci&#243;n de la di&#225;lisis y EAP. </p>
      <p>En nuestro an&#225;lisis, la hipertensi&#243;n no se asoci&#243; con ITB alto o bajo, una observaci&#243;n tambi&#233;n referida por Cheung et al<sup>2 </sup>y Jaar et al<sup>23</sup>. La hipertensi&#243;n est&#225; ampliamente presente en pacientes en HD, con una prevalencia que puede llegar a un 80% en algunas poblaciones, lo que hace la identificaci&#243;n de su efecto sobre un subgrupo espec&#237;fico dif&#237;cil de demostrar<sup>24</sup>.</p>
      <p>Cabe destacar que Rajagopalan et al<sup>8</sup> encontraron una asociaci&#243;n positiva entre la hipertensi&#243;n y la EAP, lo que demuestra que los datos en relaci&#243;n con esta cuesti&#243;n no son acordes. </p>
      <p>Sorprendentemente, no se observ&#243; una asociaci&#243;n entre el tabaquismo y el riesgo de ITB anormal. Tal vez la baja prevalencia del tabaquismo en nuestra poblaci&#243;n pueda haber frenado este efecto. La relaci&#243;n entre el tabaquismo y EAP en los pacientes en HD fue demostrada por Cheung et al<sup>2</sup> y Rajagopalan et al<sup>8</sup>, pero no por Ono et al<sup>10</sup>.</p>
      <p>Se observ&#243; un predominio de sujetos del sexo masculino entre los pacientes con ITB alto. Hallazgos similares fueron descritos tambi&#233;n por Ono et al<sup>10</sup> y O`Hare et al<sup>17</sup>. En nuestro estudio, el riesgo ajustado de presentar ITB alto &gt; 1,3 fue 4,4 veces m&#225;s alto en el sexo masculino, cuando comparado al femenino. Las razones de esta diferencia no son claras y merecen una mayor investigaci&#243;n. </p>
      <p>Nuestro estudio presenta limitaciones. Como es un estudio observacional, una relaci&#243;n causal entre inflamaci&#243;n e ITB reducido no puede establecerse. Otra limitaci&#243;n fue el hecho de haber llevado a cabo solamente una &#250;nica medici&#243;n de PCR, a pesar de informaciones anteriores de que este par&#225;metro puede presentar inestabilidad con el paso del tiempo, reflejando cambios transitorias en el estado inflamatorio<sup>25</sup>.</p>
      <p>En conclusi&#243;n, el presente estudio ha evaluado un gran n&#250;mero de pacientes en HD de mantenimiento a fin de analizar la asociaci&#243;n entre los factores de riesgo tradicionales y no tradicionales para la enfermedad cardiovascular e &#237;ndice tobillo brazo. La diabetes estaba asociada con &#237;ndice tobillo-brazo alto y bajo. La edad m&#225;s avanzada y la inflamaci&#243;n estaban asociadas al riesgo de presentar el &#237;ndice tobillo-brazo bajo, mientras que el trastorno mineral &#243;seo estaba asociado con &#237;ndice tobillo-brazo alto.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de Disertaci&#243;n de Maestr&#237;a de Jair Baptista Miguel, por la <italic>Universidade Federal Fluminense</italic>.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
